Mission Therapeutics: Valuation, Funding & Investors
Mission Therapeutics is a clinical-stage biotech company specializing in the development of first-in-class therapeutics that enhance mitophagy to promote cell and organ health. The company focuses on targeting mitochondrial dysfunction, a key factor in various diseases, including Parkinson's disease, acute kidney injury, and heart failure. Their lead candidate, MTX325, is a USP30 inhibitor designed to improve mitochondrial quality and is currently in clinical development for Parkinson's disease.
Leadership & Board
- Current Number of Employees
- 11
- Current LinkedIn Followers
- 9,449
Latest Estimated Valuation
- Total Amount Raised
- $13M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $13M
- Latest Funding Round
- Investment
Company Momentum
PositiveMission Therapeutics LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Mission Therapeutics had 11 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Mission Therapeutics had 9,449 followers as of November 16, 2026. The number of followers increased by 15 (0.16%) week-over-week.
Main Enterprise Clients
A snapshot of major enterprise customers that use this private company’s products or services, highlighting its commercial reach and market adoption.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 15, 2025 | Investment | $13.30M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| SR One | Investment |
| Sofinnova Partners | Investment |
| Roche Venture Fund | Investment |
| Pfizer Venture Investments | Investment |
| IP Group | Investment |
| Rosetta Capital | Investment |
Similar Companies
A snapshot of private companies similar to Mission Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis







